Efficacy and Safety of Remimazolam for Procedural Sedation: A Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Background: Remimazolam is a new ultrashort-acting benzodiazepine. Remimazolam has been approved for procedural sedation by the US Food and Drug Administration in 2020. However, prior trials and the participants they enrolled were limited.Aim: In this meta-analysis, we investigated the effectiveness...

Full description

Bibliographic Details
Main Authors: Bo-Jyun Jhuang, Bo-Han Yeh, Yen-Ta Huang, Pei-Chun Lai
Format: Article
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Medicine
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.641866/full